AdvanCell
- Health & Biotech
- Andover, Massachusetts, US
- Founded 2020
- Private
- advancell.com.au
Radiopharmaceutical company developing lead-212 targeted alpha therapies for cancer and building its own isotope manufacturing.
$315MEquity raised in 2025–20262025 — · 2026 $315M · 1 equity round
$315MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. AdvanCell was founded in 2020 and raised before 15 Jul 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series DAmount$315MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 14
- Ally Bridge Group1
- Alpha Wave Global1
- Abingworth
- Bain Capital Life Sciences
- Brandon Capital
- Catalio Capital Management
- Eli Lilly
- Eventide Asset Management
- Fidelity
- Morningside
- Sanofi
- SV Health Investors
- T. Rowe Price
- Velosity Capital
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
OMass TherapeuticsHealth · $310M in 2025–2026Shared: Bain Capital Life Sciences, SV Health Investors +1Cerebras SystemsAI Infra · $7.7B in 2025–2026Shared: Alpha Wave Global, FidelityRampFintech · $3.6B in 2025–2026Shared: Alpha Wave Global, Fidelity +1Parabilis MedicinesHealth · $975M in 2025–2026Shared: Fidelity, T. Rowe Price +1AnthropicAI Labs · $113B in 2025–2026Shared: Fidelity, T. Rowe PriceDatabricksEnterprise · $10B in 2025–2026Shared: Fidelity, T. Rowe Price
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. AdvanCell and its logo are trademarks of their owners, used here for identification only.
